Financing & Review - In October 2025, the North Exchange issued 3 new stocks, raising a total of 668 million yuan; from January to October 2025, a total of 19 new stocks were issued, raising 5.834 billion yuan[5] - As of now, there are 10 companies that have passed the review but have not registered, with a proposed fundraising amount of 3.220 billion yuan; 2 companies have registered but not issued, with a proposed fundraising amount of 461 million yuan[5] Subscription & Issuance - The median first-day increase for the 3 new stocks listed in October was +281.31%, with individual increases of +347.50%, +281.31%, and +180.26% for Aomeisen, Changjiang Nengke, and Taikai Ying respectively; there were no first-day declines for new stocks from January to October[3] - The theoretical subscription yield for individual new stocks Aomeisen, Changjiang Nengke, and Taikai Ying was +0.077%, +0.059%, and +0.070% respectively[3] Market Trends & Predictions - The cumulative subscription yield for new stocks on the North Exchange in 2024 was +4.01%, while the cumulative theoretical yield from January to October 2025 was +1.96%[3] - The average top subscription amount in October was 10.03 million yuan, with a median frozen fund range of 613.017 to 772.537 billion yuan[5] Investment Analysis - The China Securities Regulatory Commission has indicated a normalization of the issuance and listing process, with expectations for 40 new stocks to be issued throughout the year, potentially increasing annual subscription yields by over 3 percentage points[6] - The average lock-up period for institutions that have released shares is 8 months, with an overall yield of +254.8% and a success rate of 100%[6] Risk Factors - Potential risks include slower-than-expected issuance speed on the North Exchange, lower-than-expected stock price increases, macroeconomic downturns, and rapid growth in new stock subscription accounts[6]

IPO Review and Registration Progress - Four companies passed the IPO review last week, including Jianxin Superconductor, Muxi Co., Shuangxin Environmental Protection, and Aishalen [3][4] - Jianxin Superconductor focuses on the R&D, production, and sales of core components for MRI equipment, with projected revenues of 359 million, 451 million, and 425 million yuan from 2022 to 2024 [3] - Muxi Co. specializes in high-performance GPU chips and plans to raise 3.904 billion yuan through its IPO [3][4] - Shuangxin Environmental Protection reported a revenue decline of 25.25% and 7.85% for 2023 and 2024, respectively, due to industry downturns [4][5] - Aishalen, primarily engaged in OEM for medical care pads, expects revenues of 692 million yuan in 2024 [5] Upcoming IPOs - Three companies are set to undergo IPO reviews this week, including Jiangtian Technology, Taijin New Energy, and Hongban Technology [6] - Jiangtian Technology, which focuses on label printing, reported revenue growth from 384 million yuan in 2022 to 538 million yuan in 2024 [6] - Taijin New Energy, involved in high-end green electrolytic equipment, expects revenues to grow from 1.005 billion yuan in 2022 to 2.194 billion yuan in 2024 [7] - Hongban Technology, specializing in printed circuit boards, achieved a revenue increase of 43.48% year-on-year for the first three quarters of 2025 [8] New Stock Listings and Subscriptions - Four new stocks are scheduled to be listed this week, including Heyuan Bio, Taikang Ying, Xi'an Yicai, and Bibete [12] - Heyuan Bio is a biopharmaceutical company with eight drugs in the pipeline, while Taikang Ying focuses on mining and construction tires [12] - Xi'an Yicai, specializing in 12-inch silicon wafers, reported a revenue of 1.933 billion yuan for the first three quarters of 2025 [13] - Bibete, a biopharmaceutical firm, has no revenue but has one innovative drug approved for market [13] Recent IPO Approvals - Two companies, Angrui Micro and Yuxun Co., received IPO registration approvals, both from the "hard technology" sector [11] - Angrui Micro specializes in RF front-end chips, while Yuxun Co. focuses on optical communication front-end transceiver chips [11] Financial Performance Highlights - Jianxin Superconductor's net profits are projected to grow from 35 million yuan in 2022 to 56 million yuan in 2024 [3] - Shuangxin Environmental Protection anticipates a net profit of 52.5 million yuan in 2025, a slight increase from previous years [4] - Hongban Technology's net profit surged by 306.91% year-on-year for the first three quarters of 2025 [8] - Taijin New Energy's new signed orders for electrolytic equipment dropped significantly, raising concerns about future performance [7]

Core Viewpoint - The article discusses the recent IPO activities in the Chinese stock market, highlighting the significance of the subscription process and the expected performance of new stocks, particularly focusing on Dana Biotechnology and Zhongcheng Consulting. Group 1: IPO Performance - Dana Biotechnology's subscription is noted to be relatively easy but significant, with results expected to provide important reference for future subscriptions, especially for fractional shares [1] - Marco Polo's stock debuted with a significant opening increase of 140.73%, closing with a rise of 128.80% at 31.46 yuan, with a total trading volume of 75.7042 million shares and a turnover of 2.582 billion yuan, indicating a high turnover rate of 77.36% [1] - A single subscription for Marco Polo could yield a profit of 8,855 yuan [1] Group 2: Upcoming IPOs and Subscription Details - Dapeng Industrial, a leading manufacturer in precision cleaning equipment, is set to raise approximately 129 million yuan through its IPO [1] - Zhongcheng Consulting is expected to issue up to 14 million shares, with around 12.6 million shares available for online subscription after accounting for a 10% reduction [4] - The estimated subscription amount for Zhongcheng Consulting is projected to be between 720 billion to 730 billion yuan, indicating a high demand for shares [5] Group 3: Subscription Requirements - The top subscription limit for Zhongcheng Consulting is estimated at approximately 900.9 million yuan, with a minimum funding requirement of around 579.37 million yuan for the shares [5] - The competition for fractional shares in Zhongcheng Consulting is expected to be intense, with a minimum funding threshold likely starting at 600 million yuan, potentially reaching 650 million yuan [5]

Core Viewpoint - The IPO review process in China is accelerating, with 67 companies scheduled for meetings this year, surpassing the total from the previous year, indicating a significant increase in market activity [1][5]. Group 1: Upcoming IPOs - Four companies, including Jianxin Superconductor, Muxi Co., Shuangxin Environmental Protection, and Aisheren, are set for IPO meetings from October 20 to 24 [1][3]. - Jianxin Superconductor and Muxi Co. are applying for IPOs on the Sci-Tech Innovation Board, while Shuangxin Environmental Protection aims for the Shenzhen Main Board and Aisheren for the Beijing Stock Exchange [3]. - Among these companies, Shuangxin Environmental Protection is projected to achieve approximately 1.797 billion yuan in revenue and 281 million yuan in net profit for the first half of 2025 [3]. Group 2: Fundraising Amounts - Muxi Co. leads in proposed fundraising, aiming to raise about 3.904 billion yuan, followed by Shuangxin Environmental Protection at 1.865 billion yuan, Jianxin Superconductor at 775 million yuan, and Aisheren at 300 million yuan [4]. Group 3: IPO Statistics - A total of 67 companies have been scheduled for IPO meetings this year, compared to 57 last year, with 69 meetings held [5]. - The distribution of IPOs includes 20 from the Main Board, 8 from the Growth Enterprise Market, 26 from the Beijing Stock Exchange, and 13 from the Sci-Tech Innovation Board [5]. - The current IPO backlog consists of 275 companies, with 169 from the Beijing Stock Exchange, representing over 61% of the total [7]. Group 4: Market Trends - The acceleration in IPO reviews is attributed to deeper reforms in China's capital markets and optimized regulatory policies, with expectations for further improvements in review efficiency and stricter standards [6]. - The majority of the 275 companies in the IPO queue have had their applications accepted in 2023, indicating a robust pipeline for future listings [7].

Core Viewpoint - The company Aisheren is facing significant challenges in its IPO application due to high customer concentration, insufficient R&D investment, doubts about revenue authenticity, and contradictions in fundraising project disclosures [1][2][3]. Group 1: Financial Performance - Aisheren's net profit increased from 62.80 million yuan in 2022 to 80.61 million yuan in 2024, with a 44.81% year-on-year revenue growth in the first half of 2025 [1]. - The company's sales heavily rely on a single major client, Medline Group, with sales proportions of 71.51%, 73.08%, 71.00%, and 77.73% from 2022 to the first half of 2025 [1]. Group 2: Customer Dependency - Over 90% of Aisheren's revenue comes from overseas markets, with foreign sales accounting for 90.99%, 94.25%, 94.71%, and 96.54% of total revenue during the reporting periods [2]. - The high dependency on a limited number of clients poses a risk to the company's operational stability and bargaining power [2]. Group 3: R&D Investment - Aisheren's R&D expenses were 3.66 million yuan, 4.91 million yuan, and 7.86 million yuan from 2022 to 2024, representing only 0.64%, 0.85%, and 1.14% of revenue, significantly lower than the industry average of over 3% [3]. - The company has only 11 R&D personnel, making up just 0.57% of the total workforce, which is substantially lower than competitors like ZhenDe Medical and Aomei Medical [3][4].

Core Insights - Four companies are set to present their IPO applications, with a focus on various sectors including environmental protection, medical imaging, and artificial intelligence [1] Group 1: Upcoming IPOs - Double Xin Environmental Protection plans to list on the Shenzhen Main Board, aiming to raise 1.865 billion yuan for projects related to PVB resin and functional films, among others [1][2] - Two companies, Jianxin Superconductor and Muxi Co., are targeting the Sci-Tech Innovation Board (STAR Market) with proposed fundraising amounts of 775 million yuan each [1][3] - Aishalen is preparing for an IPO on the Beijing Stock Exchange, with a target of raising 300 million yuan [1][4] Group 2: Company Profiles - Double Xin Environmental Protection specializes in the research, production, and sales of PVA and related products, boasting a full industry chain layout [2] - Jianxin Superconductor focuses on the development and production of core components for medical MRI equipment [3] - Muxi Co. is engaged in the research, design, and sales of full-stack GPU products for AI training and general computing [3] - Aishalen is dedicated to the medical health sector, producing disposable medical supplies for rehabilitation and protection [4]

IPO and Financing Overview - Four companies are scheduled for IPO review next week (October 20-24), aiming to raise a total of 6.844 billion yuan [1] - Two companies are set for refinancing, with a total planned fundraising of 1.3 billion yuan [5] Company Summaries 1. Jianxin Superconducting Technology Co., Ltd. - The company plans to reduce its fundraising target from 865 million yuan to 775 million yuan, removing the supplementary working capital project [2] - Jianxin focuses on the R&D, production, and sales of core components for MRI equipment, including superconducting magnets, which account for approximately 50% of the cost of MRI equipment [7] - The company has been a pioneer in the mass production of high-field superconducting magnets in China, breaking the long-standing monopoly of foreign manufacturers since 2015 [7] 2. Muxi Integrated Circuit (Shanghai) Co., Ltd. - Muxi specializes in the R&D, design, and sales of high-performance GPU chips and computing platforms, targeting AI training and inference applications [10] - The company has established itself as one of the few in China with comprehensive capabilities in high-performance GPU chip development [10] 3. Shuangxin Environmental Protection Materials Co., Ltd. - Shuangxin is engaged in the R&D, production, and sales of products along the PVA (polyvinyl alcohol) industry chain, including PVA and its specialty fibers [15] - The company has a complete PVA industry chain layout and is controlled by Inner Mongolia Shuangxin Energy Chemical Co., Ltd. [15] 4. Aishalen Medical Technology Group Co., Ltd. - Aishalen focuses on the R&D, production, and sales of disposable medical consumables for rehabilitation and medical protection [19] - The company provides a range of medical dressing products, including medical care pads and surgical gowns [19] Financial Performance Jianxin Superconducting - Total assets as of June 30, 2025, were 688.99 million yuan, with a net profit of 31.92 million yuan for the first half of 2025 [9] - The company has maintained a steady increase in revenue, with a net profit margin of 6.64% [9] Muxi Integrated Circuit - As of March 31, 2025, total assets were approximately 1.046 billion yuan, but the company reported a net loss of 232.51 million yuan for the first quarter of 2025 [12] Shuangxin Environmental Protection - For the first half of 2025, total assets were 623.58 million yuan, with a net profit of 281.08 million yuan [17] - The company has shown a consistent revenue stream, with a net profit margin of 5.95% [17] Aishalen Medical Technology - As of June 30, 2025, total assets were approximately 1.201 billion yuan, with a net profit of 49.43 million yuan [21] - The company has demonstrated a stable growth trajectory, with a net profit margin of 6.61% [21]

Group 1 - The report highlights that the recent global market downturn has led to a limited adjustment in the North Exchange, with the North 50 index showing a smaller decline compared to other major indices, indicating a potential valuation advantage for growth stocks [1][9][19] - The North Exchange's price-to-earnings (PE) ratio as of October 17, 2025, is 48.34X, which is lower than the PE ratios of the ChiNext and Sci-Tech boards, suggesting a narrowing valuation gap with the ChiNext and a widening discount compared to the Sci-Tech board [17][19][22] - The report emphasizes the importance of focusing on technology growth and undervalued stocks, particularly those with strong performance in the upcoming quarterly reports [40][41] Group 2 - The North Exchange has seen a decline in liquidity, with average daily trading volume dropping to 181.85 billion yuan and turnover rate to 3.87% from previous higher levels [12][20][24] - The report notes that the North Exchange has a significant number of companies with high PE ratios, with 140 companies exceeding 45X, indicating a potential risk in overvaluation [33][36] - The report suggests that investors should pay attention to companies with stable performance and reasonable valuations, particularly in sectors like high-end equipment, information technology, and chemical new materials, which have varying PE ratios [34][37][42]